RMC No. 101-2020 publishes the FDA addendum to VAT-exempt drugs for hypertension, diabetes, and high cholesterol under RA 11467.

Businesses selling, purchasing, prescribing, distributing, or accounting for medicines for hypertension, diabetes, and high cholesterol must immediately check whether their drug databases, point-of-sale systems, invoices, tax coding, and VAT treatment reflect the expanded list of VAT-exempt medicines recognized through RMC No. 101-2020. The key compliance point is practical: covered drugs identified in the FDA addendum should be treated as VAT-exempt, and pharmacies, hospitals, clinics, distributors, accounting teams, and tax officers should ensure that their billing and tax reporting do not treat covered medicines as VATable items.

What RMC No. 101-2020 Changed

RMC No. 101-2020 published, for the information and guidance of internal revenue officers, employees, and all others concerned, the full text of the letter dated May 28, 2020 from Rolando Enrique D. Domingo, Director General of the Food and Drug Administration of the Department of Health. The letter contained the Addendum to the List of VAT-Exempt Drugs for Hypertension, Diabetes and High Cholesterol pursuant to Section 1 of Republic Act No. 11467.

The most important change is that the VAT-exempt medicines list was supplemented. RMC No. 101-2020 expressly states that it is a supplement to Revenue Memorandum Circular No. 62-2020, which had published the initial list of VAT-exempt drugs for hypertension, diabetes, and high cholesterol based on the FDA letter dated March 2, 2020. In other words, taxpayers should not rely only on the initial RMC No. 62-2020 list. They must also consider the additional FDA-identified medicines covered by the addendum published under RMC No. 101-2020.

For tax managers and corporate accountants, the searchable compliance phrase is: VAT-exempt drugs for hypertension diabetes high cholesterol. The issuance is also directly relevant to searches for RMC 101-2020 VAT exempt medicines, RA 11467 VAT exemption drugs, FDA addendum VAT-exempt drugs, and BIR VAT treatment of medicines.

Who Is Affected

RMC No. 101-2020 affects businesses and professionals involved in the sale, purchase, distribution, invoicing, tax reporting, or reimbursement of covered medicines. The most directly affected taxpayers are pharmacies, drug stores, hospital pharmacies, clinics, medical suppliers, pharmaceutical distributors, and healthcare institutions that issue invoices or receipts for medicines used for hypertension, diabetes, and high cholesterol.

The circular also matters to businesses with employee medical benefit programs, health maintenance arrangements, reimbursement policies, or procurement systems that classify medicines by VAT status. A corporate purchaser or finance department that pays for medicines, processes reimbursements, or reviews supplier invoices should confirm whether covered drugs are correctly classified as VAT-exempt. This is especially important where accounting systems automatically apply VAT coding based on product categories, supplier setup, or historical tax treatment.

Internal revenue officers are also specifically addressed by the circular. The stated audience is all internal revenue officers and others concerned, meaning that BIR personnel are expected to use the FDA addendum as guidance in applying the VAT exemption recognized under Republic Act No. 11467 and in relation to the earlier RMC No. 62-2020 list.

Key Compliance Requirements and Dates

The issuance date appearing on RMC No. 101-2020 is September 21, 2020. The underlying FDA letter referred to in the circular is dated May 28, 2020. The earlier FDA letter that served as basis for RMC No. 62-2020 is dated March 2, 2020. These dates matter because they show that RMC No. 101-2020 is not a replacement of the earlier circular, but a supplement expanding or adding to the initial VAT-exempt list.

The circular does not prescribe a separate filing deadline, registration deadline, or transition procedure. Its operative instruction is that all concerned are enjoined to be guided accordingly and to give the circular as wide publicity as possible. For businesses, this means the compliance action is immediate operational alignment: update product master files, VAT codes, billing templates, inventory classifications, procurement workflows, and invoice review protocols so that medicines covered by the FDA addendum are not incorrectly treated as VATable.

The circular also does not provide a tax rate table, medicine-by-medicine pricing table, or taxpayer threshold. The relevant tax consequence is the VAT-exempt classification for drugs in the FDA addendum for hypertension, diabetes, and high cholesterol pursuant to Section 1 of Republic Act No. 11467. Taxpayers should therefore focus on documentary and system controls rather than threshold computations.

Penalties and Risk Areas for Non-Compliance

RMC No. 101-2020 does not state a standalone penalty, surcharge, or interest rate for non-compliance. It also does not create a separate penalty regime for pharmacies, hospitals, distributors, or other sellers of medicines. However, the practical tax risk is clear: if a covered medicine is incorrectly coded, invoiced, or reported, the taxpayer may create VAT reporting inconsistencies, customer overcharging issues, accounting mismatches, and audit questions regarding the proper tax treatment of VAT-exempt medicines.

From a business standpoint, the highest-risk points are product setup, cashier or point-of-sale tax coding, supplier invoice validation, and monthly or quarterly VAT reporting. A medicine may be correctly identified by the FDA addendum but still be treated incorrectly if the accounting or inventory system was not updated after RMC No. 101-2020. For companies with multiple branches, the compliance risk is multiplied if only the head office updates the policy while branches continue to use outdated VAT classifications.

Practical Steps for Businesses

First, businesses should identify all products in their inventory or procurement system that fall within medicines for hypertension, diabetes, and high cholesterol. The purpose is to isolate items that may be covered by the VAT-exempt list and the addendum published under RMC No. 101-2020.

Second, finance and tax teams should compare current product VAT codes against the initial list under RMC No. 62-2020 and the addendum recognized in RMC No. 101-2020. Since the circular is expressly described as a supplement to RMC No. 62-2020, compliance should cover both the initial list and the addendum, not one or the other.

Third, businesses should coordinate with pharmacy operations, purchasing, warehouse, and IT teams to ensure that point-of-sale systems and accounting software reflect the proper VAT-exempt classification. This is particularly important for companies that use automated invoicing or enterprise resource planning systems where a single incorrect product setup can generate repeated incorrect invoices across branches.

Fourth, accounting teams should review recent invoices, official receipts, sales reports, and VAT schedules for covered medicines. The review should determine whether the medicines were treated consistently with the VAT-exempt classification. Where inconsistencies are found, the company should evaluate the corrective action required under its tax reporting and customer documentation procedures.

Finally, businesses should keep a compliance file containing RMC No. 101-2020, RMC No. 62-2020, the relevant FDA communications referenced by the circular, internal tax memos, and proof of system updates. This file will help explain the basis for the VAT treatment during internal review, external audit, supplier reconciliation, or BIR examination.

Why This Matters for CFOs and Tax Teams

RMC No. 101-2020 is short, but it has direct operational consequences. The circular tells taxpayers that the VAT-exempt list for hypertension, diabetes, and high cholesterol drugs did not stop with the initial list in RMC No. 62-2020. The FDA addendum recognized by the BIR must be integrated into tax compliance systems. For CFOs, the issue is not only legal interpretation. It is whether the company’s people, invoices, software, and reporting schedules actually apply the exemption correctly.

For pharmacies, healthcare companies, pharmaceutical distributors, clinics, hospitals, and corporate medical benefit administrators, the safest approach is to treat RMC No. 101-2020 as a required tax-coding update. A missed update can lead to recurring invoice errors and difficult reconciliations. A documented update, on the other hand, gives management a defensible basis for treating covered medicines as VAT-exempt.

ASG Law Can Assist with BIR VAT Compliance

Ablola, Saribong & Gueco advises businesses, healthcare providers, pharmaceutical suppliers, corporate finance teams, and tax departments on BIR issuances, VAT classification, invoicing compliance, and tax audit readiness. If your business sells, purchases, reimburses, or accounts for medicines covered by RMC No. 101-2020, ASG Law can help review your VAT treatment, internal controls, invoice wording, and compliance documentation.

For assistance with BIR compliance, VAT-exempt drug classification, tax audit preparation, or corporate tax advisory work in the Philippines, contact Ablola, Saribong & Gueco through MakatiLawFirm.com.


Leave a Comment

Your email address will not be published. Required fields are marked *